Micreos is a platform biotech company focused on the discovery and development of recombinant proteins for chronic dermatological conditions. The company specializes in engineered endolysin technology, which aims to eliminate harmful pathogens while preserving the health-enhancing microbiome. Micreos's lead therapeutic candidate, MEndoB, is an engineered endolysin that targets Staphylococcus aureus, a pathogen associated with Atopic Dermatitis, with the goal of restoring the skin's natural microbiome. It was founded in 2005 and is based in Baar, Switzerland.

Locus Biosciences focused on developing engineered bacteriophage therapies. The company works on precision medicine for infectious diseases and immunologic conditions, utilizing a technology stack that includes artificial intelligence, robotics, and synthetic biology to create targeted phage treatments. Locus Biosciences serves the medical research and pharmaceutical development sectors. It was founded in 2015 and is based in Morrisville, North Carolina.

Novolytics, formed in 2002, engages in the research, development, and production of phage therapy products to combat antibiotic resistance.

PhageNova Bio focuses on targeted gene expression technologies in the biopharmaceutical sector, particularly in cancer treatment and vaccine development. The company has developed a gene delivery vector that aims to deliver therapies to tumor cells while reducing effects on normal cells. PhageNova Bio's offerings include a cancer asset for solid tumors and a phage-based vaccination platform targeting COVID-19. It was founded in 2012 and is based in Summit, New Jersey.

NexaBiome develops antibiotics and solutions to combat antimicrobial resistance. The company specializes in bacteriophage technology, which includes the identification, isolation, production, and formulation of phages to treat drug-resistant infections and enhance food supply sustainability. NexaBiome's products target both human and animal health, focusing on pathogens and the microbiome for health applications. NexaBiome was formerly known as Fixed Phage. It was founded in 2010 and is based in Glasgow, United Kingdom.

Phagelux AgriHealth develops biological alternatives to chemicals and antibiotics for agriculture. The company offers products that control food safety pathogens, reduce bacterial losses in agriculture, and serve the agriculture sector with solutions for crops and livestock. The company was founded in 2014 and is based in Nanjing, China.